Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Buys Genomics Service Provider Aros

NEW YORK (GenomeWeb News) – Eurofins Scientific today announced it has bought genomics service provider Aros Applied Biotechnology for an undisclosed amount.

Based in Aarhus, Denmark, Aros services the pharmaceutical industry as well as academia and public research institutes. The deal expands Eurofins' genomics services footprint into the Nordic region.

Founded in 2000, Aros generates revenues of about €10 million ($13.2 million) and provides next-generation sequencing services to the pharma industry. Its capabilities, which also include genotyping and gene expression profiling, will complement Eurofins' current NGS services, which are offered through its Eurofins MWG Operon business.

The deal allows Eurofins to expand its share of the high-growth NGS market targeted to pharma "by leveraging its increased scale," it said, adding that Aros will now have access to an expanded portfolio of genomic services.

According to Aros' website, the company provides sample banking, extraction of molecules, microarray analysis, PCR-based testing, and bioinformatics services, as well as NGS services. The platforms it uses include those from Affymetrix, Illumina, Agilent Technologies, Qiagen, Fluidigm. and Life Technologies' Applied Biosystems.

"Aros is an excellent strategic fit with Eurofins' genomic services business," Eurofins CEO Gilles Martin said in a statement. "It expands our geographical footprint for our genomics offering, and their competence is entirely consistent with our focus on high-quality next-generation sequencing. We remain committed to strengthening our market position in genomic services, as we believe that technological advancements in sequencing equipment will eventually enable mass application of NGS across industries."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.